DNM1L and cancer: In addition to corroborating the previously reported the clinical significance of MHC-I and pSer616 DRP-1 expression levels17,18, our results, namely, the negative correlation between pSer616 DRP-1 and MHC-I expression levels, prompted us to hypothesize that targeting mitochondrial fission may represent a strategy to enhance MHC-I expression by cancer cells.